Arsmeda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 654,023 | 1,081,082 | 1,254,804 | 909,898 | 1,713,187 | 1,943,719 | 2,451,927 | 4,417,026 |
| Profit before tax | 155,021 | 278,342 | 227,280 | 276,990 | 533,081 | 618,976 | 741,562 | 1,366,967 |
| Net profit | 131,728 | 234,750 | 191,767 | 235,427 | 451,613 | 525,727 | 629,814 | 1,148,218 |
| Equity | 221,873 | 456,623 | 648,389 | 883,816 | 1,335,429 | 1,861,156 | 2,490,971 | 3,639,189 |
| Liabilities | 23,684 | 45,452 | 38,937 | 45,767 | 182,502 | 99,411 | 112,780 | 110,682 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 1,617 | 3,410 | 2,518 |
| Current assets | 244,632 | 502,075 | 687,316 | 929,560 | 1,517,898 | 1,952,848 | 2,600,110 | 3,747,302 |
| Total assets | 244,632 | 502,075 | 687,316 | 929,560 | 1,517,898 | 1,954,465 | 2,603,520 | 3,749,820 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 129,752 | 152,721 | 151,562 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +143.0% | +65.3% | +16.1% | -27.5% | +88.3% | +13.5% | +26.1% | +80.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 53.8% | 46.8% | 27.9% | 25.3% | 29.8% | 26.9% | 24.2% | 30.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 59.4% | 51.4% | 29.6% | 26.6% | 33.8% | 28.2% | 25.3% | 31.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 20.1% | 21.7% | 15.3% | 25.9% | 26.4% | 27.0% | 25.7% | 26.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 23.7% | 25.7% | 18.1% | 30.4% | 31.1% | 31.8% | 30.2% | 30.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 327,012 | 540,541 | 627,402 | 454,949 | 856,594 | 897,087 | 1,225,964 | 2,120,206 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Arsmeda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-01-17 | 2023-02-01 | 0.20 |
Arsmeda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-05-13 | 2025-05-13 | 1084.03 |
| 2025-05-10 | 2025-05-12 | 1071.44 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Arsmeda, UAB (code 303280820) is a private limited liability company active in the wholesale of pharmaceutical and medical goods. In 2025, the company generated EUR 4.42M in revenue and EUR 1.15M in net profit, with a net profit margin of 26.0%. Revenue increased from EUR 1.94M in 2023 to EUR 2.45M in 2024 and then to EUR 4.42M in 2025, while net profit rose from EUR 525.7K to EUR 629.8K and then to EUR 1.15M over the same period. The balance sheet remained very strong, with total assets of EUR 3.75M, equity of EUR 3.64M and liabilities of EUR 110.7K at year-end 2025. The equity ratio was 97.0% and debt-to-equity stood at 0.03, indicating very limited leverage. Return on equity was 31.6% and return on assets 30.6%. Asset turnover reached 1.18x. Revenue per employee was EUR 2.21M, and profit per employee was EUR 574.1K, pointing to high operating productivity.